Drug Trial News

RSS

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

New document includes practical resources to improve diversity and inclusion in clinical research

The COVID-19 pandemic has illuminated social and health inequities and the impact of structural and systemic racism in society.

7 Aug 2020

Vitamin D does not reduce risk of depression or mood changes

Several studies have shown that those with Vitamin D deficiency also have symptoms of depressive illness. The authors wrote, "Low levels of 25-hydroxyvitamin D have been associated with a higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials."

5 Aug 2020

Panthera’s oncology clinical trial sites in the UK are open for research activities

Over a thousand oncology clinical trials have been suspended due to Covid putting back research which is vital for patients across the world.

5 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG.

4 Aug 2020

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

4 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Broad range of therapeutics are being evaluated for Parkinson's disease

A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated.

4 Aug 2020

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Oxford University and the COVID Symptom Study app are joining forces to widen access to two clinical trials of potential treatments for COVID-19.

3 Aug 2020

Dexamethasone should be a standard drug in severe COVID-19

Many scientists have explored the use of new as well as already approved drugs for this condition, and one of the very few promising leads is dexamethasone. Dexamethasone is a corticosteroid, which has been reported in some earlier studies to reduce mortality in these patients by 18% and 36% in COVID-19 patients who are on oxygen and ventilators, respectively.

3 Aug 2020

The race to a coronavirus vaccine

As the number of coronavirus disease (COVID-19) cases skyrocket to a staggering 18 million, the race to attain vaccine approval is on. More than a hundred candidate vaccines are being developed and tested to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, many vaccine candidates are undergoing human stage 2 and 3 trials to prove their efficacy and safety.

2 Aug 2020

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd., a world-leading structure-based drug discovery platform today announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.

31 Jul 2020

Investigational drug shows promising results for treating HNSCC tumors

Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas (HNSCC) account for the majority of these cases.

31 Jul 2020

Women receiving treatment for cancers are not at increased of being hospitalized for COVID-19

Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.

30 Jul 2020

Pimavanserin reduced psychotic symptoms in people with dementia in phase 3 study

A large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.

29 Jul 2020

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.

29 Jul 2020

Researchers launch randomized, placebo-controlled clinical trial of pulmozyme in COVID-19 patients

Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation.

29 Jul 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

Previous
1
...
71
72
73
74
75
76
77
...
1143
Next

Drug Trial News

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

New document includes practical resources to improve diversity and inclusion in clinical research

Vitamin D does not reduce risk of depression or mood changes

Panthera’s oncology clinical trial sites in the UK are open for research activities

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Broad range of therapeutics are being evaluated for Parkinson's disease

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Dexamethasone should be a standard drug in severe COVID-19

The race to a coronavirus vaccine

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Investigational drug shows promising results for treating HNSCC tumors

Women receiving treatment for cancers are not at increased of being hospitalized for COVID-19

Pimavanserin reduced psychotic symptoms in people with dementia in phase 3 study

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers launch randomized, placebo-controlled clinical trial of pulmozyme in COVID-19 patients

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News